Multivariable Cox regression applied to the 165 patients with evaluable TP53 status revealed that CLL-CI remained a significant predictor of EFS (intermediate vs. low risk: HR = 2.18 [95%CI, 1.22–3.90], p = 0.009; high vs. low risk: HR = 2.32 [95% CI, 1.23–4.37], p = 0.009; c-index = 0.73) after adjusting for disease stage (Binet A vs. Binet B/C) and the presence of del(17p) or TP53 mutation (Fig. 1C). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.